Abstract
Aims
We determined levels of the inflammatory marker YKL-40 in a population of patients
with type 2 diabetes (T2D) and investigated the association with mortality.
Methods
In a prospective observational follow-up study, 290 patients with T2D, normoalbuminuria
(n = 177), microalbuminuria (n = 71) and macroalbuminuria (n = 42) were followed for a median (range) of 17.2 (0.2–23.0) years. Serum YKL-40 concentration
was determined at baseline.
Results
Baseline median (IQR) YKL-40 level was 46 ng/ml (36–67) in patients with normoalbuminuria, 61 ng/ml (43–114) in microalbuminuric patients, and 81.5 ng/ml (60–157) in patients with macroalbuminuria, p < 0.001. During follow-up 189 patients (65.2%) died, 119 (41.0%) from cardiovascular
causes. All-cause mortality was increased in patients with YKL-40 levels in the second
and third tertile (hazard ratios (95% CI) compared with the first tertile, (1.50 (1.03–2.19),
p = 0.034, and 2.88 (2.01–4.12), p < 0.001). This association persisted after adjustment for cardiovascular risk factors
but was attenuated after additional adjustment for urinary albumin excretion rate
and glomerular filtration rate.
Cardiovascular mortality was increased with YKL-40 levels in the third tertile compared
with the first tertile, (2.70 (1.78–4.08)), p < 0.001. This association was diminished after adjustment for covariates.
Conclusions
In patients with T2D and increasing albuminuria high YKL-40 levels predict all-cause
mortality.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Diabetes Research and Clinical PracticeAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Plasma YKL-40: a potential new cancer biomarker?.Future Oncol. 2009; 5: 1065-1082
- Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer.Dan Med Bull. 2006; 53: 172-209
- A chitinase-like protein in the lung and circulation of patients with severe asthma.N Engl J Med. 2007; 357: 2016-2027
- Serum YKL-40 levels in patients with coronary artery disease.Coron Artery Dis. 2007; 18: 391-396
- YKL-40—an emerging biomarker in cardiovascular disease and diabetes.Cardiovasc Diabetol. 2009; 8: 61
- YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance.Inflamm Res. 2006; 55: 53-59
- YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria.Diabetes Care. 2009; 32: 323-328
- Atherosclerosis—an inflammatory disease.N Engl J Med. 1999; 340: 115-126
- Increased YKL-40 expression in patients with carotid atherosclerosis.Atherosclerosis. 2010; 211: 589-595
- Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.N Engl J Med. 1998; 339: 229-234
- Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.Circulation. 2008; 117: 1945-1954
- Effect of a multifactorial intervention on mortality in type 2 diabetes.N Engl J Med. 2008; 358: 580-591
- Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate.Nephrol Dial Transplant. 2011; 26: 3242-3249
- Albuminuria and poor glycemic control predicts mortality in NIDDM.Diabetes. 1995; 44: 1303-1309
- The diagnosis of ischaemic heart pain and intermittent claudication in field surveys.Bull WHO. 1962; 27: 645-658
- The electrocardiogram in population studies: a classification system.Circulation. 1960; 21: 1160-1175
- Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients.Diabetologia. 1991; 34: 655-661
- Quantitative determination of hemoglobin A1c by thinlayer isoelectric focusing.J Chromatogr. 1980; 182: 325-333
- A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.Ann Intern Med. 1999; 130: 461-470
- YKL-40 in type 2 diabetic patients with different levels of albuminuria.Eur J Clin Invest. 2011; 41: 589-596
- YKL-40 levels are independently associated with albuminuria in type 2 diabetes.Cardiovasc Diabetol. 2011; 10: 54
- Plasma YKL-40 A BMI-Independent Marker of Type 2 Diabetes.Diabetes. 2008; 57: 3078-3082
- YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis.Inflamm Res. 2006; 55: 221-227
- Plasma YKL-40 levels are elevated in patients with chronic heart failure.Scand Cardiovasc J. 2010; 44: 92-99
- YKL-40, a secreted glycoprotein, promotes tumor angiogenesis.Oncogene. 2009; 28: 4456-4468
Article info
Publication history
Published online: January 04, 2012
Accepted:
December 5,
2011
Received in revised form:
October 24,
2011
Received:
September 6,
2011
Identification
Copyright
© 2011 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
